News

According to the company, the grants will fund further research on new generations of the its drug delivery technologies targeting ophthalmic diseases. pSivida develops tiny drug delivery products

The agreement was signed together with Wanbang Biopharmaceuticals, as part of the D-Pharm – Wanbang co-development program for DP-b99 in China. Discovered and developed by D-Pharm, DP-b99 is

As per the terms of the agreement, Simcere receives exclusive rights to develop and commercialise BMS-817378 in China while Bristol-Myers Squibb retains exclusive rights in all other markets.

Supera Veritas is the delivery system for IDEV’s Supera wire interwoven nitinol stent, currently cleared in the US for palliative treatment of biliary strictures produced by malignant neoplasms.

NMT’s product development platform, based on transdermal neuromodulation technology, will be leveraged for a wide variety of emesis indications, including post-operative nausea, cancer treatment, pregnancy and motion sickness,

HepaLife said that its subsidiary, Alliqua BioMedical (Alliqua), recently retained Jeiven Pharmaceutical Consulting (Jeiven) to assist it in this new product development. Through this partnership, Alliqua intends to

Talecris Biotherapeutics claims that Prolastin-C is more concentrated and purified formulation of Prolastin, the only approved alpha1-augmentation therapy in Canada. Prolastin-C and Prolastin are indicated for chronic augmentation

The grant to GTx comprises separate payments of $244,000 for each of five cancer and cancer supportive care research and development programs. Gtx CEO Mitchell Steiner said that

Enzon Pharma has posted a net loss of $8.35m for the third quarter 2010, compared to net income of $133,000 for the comparable period in 2009. The company’s